BioBrief covers a major platform milestone as the F D A approves Veppanu, the first targeted protein degrader, for ESR1-mutated breast cancer. We also look at UCB’s 2.2 billion dollar autoimmune acquisition, Summit’s weaker ivonescimab timing story, and Celcuity’s Phase 3 breast cancer readout ahead of ASCO.

1. Arvinas / Pfizer — Veppanu
   • Mechanism: Oral estrogen receptor protein degrader
   • Indication: ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
   • Stage: FDA approval
   • Key result: Median progression-free survival of 5.0 months versus 2.1 months with fulvestrant; hazard ratio 0.57
   • Why it matters: First approved targeted protein degrader, with a narrow but clinically meaningful breast cancer label
2. UCB / Candid Therapeutics — cizutami ...